The dawn of holography technology marks a revolutionary period in healthcare, enhancing diagnostic capabilities, surgical planning, and medical education. With predictions of the global medical holography market reaching $7.11 billion by 2029, the healthcare sector stands on the brink of profound
Ivan Kairatov is a Biopharma expert, with deep knowledge in tech and innovation in the industry and experience in research and development. Today, we will discuss the intricacies of protein kinase research, the role of AI in predicting interactions, and the development of KinasePred. Can you
On March 3, 2025, Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focusing on targeting the CLEVER-1 receptor to reprogram myeloid cells for anti-tumor immunity in both hematological and solid tumors, announced a significant milestone. Their lead therapeutic candidate,
The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs c
The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can
Antibody-drug conjugates (ADCs) are emerging as a groundbreaking approach in oncology, offering the potential to revolutionize cancer treatment through targeted and effective therapies. This innovation combines the precision of targeted antibodies with the potent cell-killing ability of
